Business
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approvedCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of
About this update from Intellia Therapeutics, Inc.
[{"type":"image","alt":"Intellia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Intellia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E8KNdwU6yVQf4O84cdCx6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d","width":300,"height":150}},"lazy":false},{"type":"text","content":"Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approved","length":110,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of lonvo-z (formerly known as NTLA-2002) for hereditary angioedema (HAE). Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels.","length":715,"tagName":"p"},{"type":"text","content":"Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a one-time dose of lonvo-z led to freedom from both HAE attacks and the use of ongoing therapy for most patients during the six-month primary observation period.","length":359,"tagName":"p"},{"type":"text","content":"“If approved, lonvo-z will become the world’s first in vivo CRISPR-based gene editing therapy,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “The promising results from HAELO reinforce our conviction that lonvo-z could revolutionize how HAE is treated for many patients, with the potential to free most of them from both attacks and the need for ongoing therapy with just one dose. We look forward to our continued engagement with the FDA as we seek to...